Zogenix to Participate in the Stifel 3rd Annual CNS Day
- U.S. stocks close down on news of Biden tax proposal
- Biden To Propose Capital Gains Tax As High As 43.4% For Wealthy - Bloomberg
- Intel (INTC) Tops Q1 EPS by 24c, Offers Guidance
- Snap (SNAP) Tops Q1 EPS by 5c, DAUs were 280 million, Offers Guidance
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
EMERYVILLE, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will participate in a fireside chat on Wednesday, March 31, 2021, at the Stifel 3rd Annual CNS Day.
|Zogenix Presentation Details|
|Date: Wednesday, March 31, 2021|
|Time: 2:30 PM Eastern Time|
The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.
About ZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
ZogenixMelinda BakerSenior Director, Corporate Communications+1 (510) 788-8732 | email@example.com
InvestorsBrian Ritchie Managing Director, LifeSci Advisors LLC+1 (212) 915-2578 | firstname.lastname@example.org
MediaStefanie Tuck, Vice President, Porter Novelli+1 (978) 390-1394 | email@example.com
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Profire Energy Sets First Quarter 2021 Conference Call for Thursday, May 6, 2021 at 1:00 p.m. ET
- Treace Medical Concepts Announces Pricing of Upsized Initial Public Offering
- Camposol Holding PLC Invitation to the Presentation of Fourth Quarter and Audited Full Year 2020 Financial Results